SEC Company Response from Evogene Ltd. (EVGN) (CIK 0001574565) (EVGN) — Nov 18, 2013
Evogene Ltd. (EVGN) (CIK 0001574565)
Date: Nov. 18, 2013 · CIK: 0001574565 · Accession: 0001193125-13-445356
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191315
Letter
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS
Acceleration Request
November 18, 2013
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Evogene Ltd. (CIK No. 0001574565)
Registration Statement on Form F-1 (File No. 333-191315)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Evogene Ltd. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333-191315), as amended, to 4:00 p.m., Eastern Time, on Wednesday, November 20, 2013, or as soon thereafter as practicable.
The Company hereby acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions regarding this letter, please do not hesitate to contact Joshua Kiernan or Jessica Chen at (212) 819-8503 of White & Case LLP, counsel to the Company.
[Remainder of Page Intentionally Blank]
Sincerely,
EVOGENE LTD.
By:
/s/ Sigal Fattal
Name:
Sigal Fattal
Title:
Chief Financial Officer
November 18, 2013
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Evogene Ltd.
Registration Statement on Form F-1 (SEC File No. 333-191315)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Evogene Ltd. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern time, on November 20, 2013 or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 3,000 copies of the Preliminary Prospectus dated November 6, 2013 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
CREDIT SUISSE SECURITIES (USA) LLC
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request November 18, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Evogene Ltd. (CIK No. 0001574565) Registration Statement on Form F-1 (File No. 333-191315) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Evogene Ltd. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333-191315), as amended, to 4:00 p.m., Eastern Time, on Wednesday, November 20, 2013, or as soon thereafter as practicable. The Company hereby acknowledges that: • should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Should you have any questions regarding this letter, please do not hesitate to contact Joshua Kiernan or Jessica Chen at (212) 819-8503 of White & Case LLP, counsel to the Company. [Remainder of Page Intentionally Blank] Sincerely, EVOGENE LTD. By: /s/ Sigal Fattal Name: Sigal Fattal Title: Chief Financial Officer November 18, 2013 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Evogene Ltd. Registration Statement on Form F-1 (SEC File No. 333-191315) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Evogene Ltd. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern time, on November 20, 2013 or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 3,000 copies of the Preliminary Prospectus dated November 6, 2013 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others. In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, CREDIT SUISSE SECURITIES (USA) LLC DEUTSCHE BANK SECURITIES INC. As Representatives By: CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Spyros Svoronos Name: Spyros Svoronos Title: Managing Director By: DEUTSCHE BANK SECURITIES INC. By: /s/ Francis Windels Name: Francis Windels Title: Managing Director By: /s/ Benjamin Marsh Name: Benjamin Marsh Title: Director